167 results on '"Gerolami, René"'
Search Results
2. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors
3. Limosilactobacillus fermentum, Lactococcus lactis and Thomasclavelia ramosa are enriched and Methanobrevibacter smithii is depleted in patients with non-alcoholic steatohepatitis
4. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)
5. THU-079 Pre-transplant work-up for acute-on-chronic liver failure patients in intensive care units, a nationwide french survey
6. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
7. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
8. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
9. Parcours de soins du patient atteint de carcinome hépatocellulaire en France : état des lieux en 2017
10. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
11. Culturomics study of gut microbiota in NASH patients and healthy controls
12. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase
13. Transjugular intrahepatic porto-systemic shunt is a risk factor for liver dysplasia but not hepatocellular carcinoma: A retrospective study of explanted livers
14. Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
15. Liver transplantation for acute liver failure related to autochthonous genotype 3 hepatitis E virus infection
16. Fatal Fulminant Hepatitis E in a Diabetic Patient on Metformin
17. Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up
18. Two Years' Persistence of Naturally Present Substitution R155K Within Hepatitis C Virus NS3 Protease in the Absence of Protease Inhibitor-based Therapy
19. Pig Liver Sausage as a Source of Hepatitis E Virus Transmission to Humans
20. Epidemiological, Clinical, Virological Features of Hepatitis B Newly Diagnosed in 2011 in Marseille University Hospitals, Southeastern France
21. Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France
22. Whipple Disease Associated with Giardiasis
23. Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
24. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)
25. DNA-repair and carcinogen-metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients
26. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers
27. Chronic hepatitis E in absence of severe immune deficiency
28. Gene transfer to hepatocellular carcinoma: Transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors
29. THU-247 - Culturomics study of gut microbiota in NASH patients and healthy controls
30. Sphincter of oddi manometry: Paradoxical response to secretin but not to CCK in alcoholic patients with no pancreatic disease
31. A squalamine derivative, NV669, as a novel PTP1B inhibitor: in vitro and in vivo effects on pancreatic and hepatic tumor growth
32. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors
33. Whipple’s disease: immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens
34. Liver transplantation for hepatocellular carcinoma after down staging with sorafenib: a monocentric case-matched series
35. A squalamine derivative, NV669, as a novel PTP1B inhibitor:in vitroandin vivoeffects on pancreatic and hepatic tumor growth
36. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
37. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
38. Evolution of hepatitis E virus-associated meningo-polyradiculoneuropathy on ribavirin
39. Nucleotide and amino acid diversity of hepatitis B virus surface antigen in acute infections, southeastern France
40. Hepatitis Delta recurrence post-liver transplantation in absence of detectable hepatitis B surface antigen and hepatitis B virus DNA in peripheral blood
41. Doxorubicin-Loaded Nanoparticles for Patients with Advanced Hepatocellular Carcinoma after Failure of Sorafenib: RELIVE, a Phase-3 Trial
42. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
43. Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial
44. Chronic hepatitis E resolution in a human immunodeficiency virus (HIV)-infected patient treated with ribavirin
45. Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy
46. Fulminant hepatitis B virus reactivation following antiviral treatment interruption in a chronically infected patient
47. Discrepancy between anti-hepatitis E virus immunoglobulin G prevalence assessed by two assays in kidney and liver transplant recipients
48. 4:12 PM Abstract No. 379 Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment
49. Circulation of almost genetically identical hepatitis E virus of genotype 4 in France
50. Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.